StockGuru Spotlight on Regen Biopharma, Inc.
(Symbol: RGBP)

Help us update information on this company. Email any updates to: [email protected]

About Regen Biopharma, Inc.:

We are a majority owned subsidiary of Bio-Matrix Scientific Group, Inc, a Delaware corporation. We intend to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials.

 

Where it is located:

4700 Spring Street
Suite 304

La Mesa, CA
91942

United States

 

Key Executive Contact:

David Koos

President, CEO, CFO

 

Ninety Day Volume:

445373 (as of date of publication)

 

Ninety Day Dollar Volume:

$120,696

 

Share Information:

shares as of

 

Corporate Information:

State Incorporated: NV

Country Incorporated: USA

 

Contact, Website and Social Media for Regen Biopharma, Inc.:

Shown Where Available

Website:

Facebook:

Twitter:

LinkedIn:

Telephone: 619-702-1404

Email:

 

 

Investor Relations for Regen Biopharma, Inc.: